SEC Form 4 · accession 0001179110-16-026360
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Janney
Director
Period of report
Jun 9, 2016
Accepted (ET)
Jun 10, 2016 · 5:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $17.75 | Jun 9, 2016 | A | 8,000 | A | — | Jun 9, 2026 | Common Stock | 8,000 | 8,000 | D |
Explanation of responses
- F1The options vest in full on the earlier of (i) June 9, 2017 and (ii) the Issuer's next annual meeting of stockholders following June 9, 2016.